Literature DB >> 23280876

Comparison of oncogenic HPV type-specific viral DNA load and E6/E7 mRNA detection in cervical samples: results from a multicenter study.

Francesco Broccolo1, Lisa Fusetti, Sandra Rosini, Donatella Caraceni, Roberta Zappacosta, Lucia Ciccocioppo, Barbara Matteoli, Philippe Halfon, Mauro S Malnati, Luca Ceccherini-Nelli.   

Abstract

High-risk human papillomavirus (HR-HPV) genotype viral load and E6/E7 mRNA detection are proposed as surrogate markers of malignant cervical lesion progression. Currently, the use of commercially available DNA-based or mRNA-based tests is under investigation. In this study, the viral DNA load and E6/E7 mRNA detection of the five most common HR-HPV types detected in cervical cancer worldwide were compared in 308 cervical samples by using in-house type-specific quantitative real-time PCR assays and PreTect HPV-Proofer test, respectively. Sensitivity and negative predictive values were higher for the HPV-DNA assays combined (95.0% and 96.0%, respectively) than the RNA assays (77.0% and 88.0%, respectively); conversely, the mRNA test showed a higher specificity and higher positive predictive value (81.7% and 66.9%, respectively) than the DNA test (58.6% and 52.5%, respectively) for detecting histology-confirmed high-grade cervical intraepithelial neoplasia. A significantly higher association between viral DNA load and severity of disease was observed for HPV 16 and 31 (γ = 0.62 and γ = 0.40, respectively) than for the other HPV types screened. A good degree of association between the two assays was found for detection of HPV 16 (k = 0.83), HPV 18 (k = 0.72), HPV 33 (k = 0.66), and HPV 45 (k = 0.60) but not for HPV 31 (k = 0.24). Sequence analysis in L1 and E6-LCR regions of HPV 31 genotypes showed a high level of intra-type variation. HR-HPV viral DNA load was significantly higher in E6/E7 mRNA positive than negative samples (P < 0.001), except for HPV 31. These findings suggest that transcriptional and replicative activities can coexist within the same sample.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23280876     DOI: 10.1002/jmv.23487

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  10 in total

1.  Clinical characteristics of women diagnosed with carcinoma who tested positive for cervical and anal high-risk human papillomavirus DNA and E6 RNA.

Authors:  Carlos A R Veo; Sarhan S Saad; José Humberto T G Fregnani; Cristovam Scapulatempo-Neto; Audrey Tieko Tsunoda; Júlio César Possati Resende; Adriana Tarlá Lorenzi; Allini Mafra; Claudia Cinti; Ismael Dale Cotrim; Luciana Albina Reis Rosa; Cristina Mendes de Oliveira; Toni Ricardo Martins; Cristiane Centrone; José Eduardo Levi; Adhemar Longatto-Filho
Journal:  Tumour Biol       Date:  2015-02-13

2.  HPV16 E6*II gene expression in intraepithelial cervical lesions as an indicator of neoplastic grade: a pilot study.

Authors:  Dorota Pastuszak-Lewandoska; Anna Bartosińska-Dyc; Monika Migdalska-Sęk; Karolina H Czarnecka; Ewa Nawrot; Daria Domańska; Krzysztof Szyłło; Ewa Brzeziańska
Journal:  Med Oncol       Date:  2014-01-17       Impact factor: 3.064

3.  The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening.

Authors:  D A M Heideman; A T Hesselink; F J van Kemenade; T Iftner; J Berkhof; F Topal; D Agard; C J L M Meijer; P J F Snijders
Journal:  J Clin Microbiol       Date:  2013-08-28       Impact factor: 5.948

4.  The role of globular heads of the C1q receptor in HPV 16 E2-induced human cervical squamous carcinoma cell apoptosis is associated with p38 MAPK/JNK activation.

Authors:  Ling-juan Gao; Ping-qing Gu; Wei Zhao; Wen-yan Ding; Xue-qing Zhao; Shu-yu Guo; Tian-ying Zhong
Journal:  J Transl Med       Date:  2013-05-08       Impact factor: 5.531

5.  Presence of High-Risk HPV mRNA in Relation to Future High-Grade Lesions among High-Risk HPV DNA Positive Women with Minor Cytological Abnormalities.

Authors:  Hanna Johansson; Kaj Bjelkenkrantz; Lotten Darlin; Joakim Dilllner; Ola Forslund
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

6.  Different Association of Human Papillomavirus 16 Variants with Early and Late Presentation of Cervical Cancer.

Authors:  Ana Alfaro; Eligia Juárez-Torres; Ingrid Medina-Martínez; Norma Mateos-Guerrero; Maura Bautista-Huerta; Edgar Román-Bassaure; Nicolás Villegas-Sepúlveda; Jaime Berumen
Journal:  PLoS One       Date:  2016-12-30       Impact factor: 3.240

7.  Separate analysis of human papillomavirus E6 and E7 messenger RNAs to predict cervical neoplasia progression.

Authors:  Shuling Liu; Takeo Minaguchi; Bouchra Lachkar; Shuang Zhang; Chenyang Xu; Yuri Tenjimbayashi; Ayumi Shikama; Nobutaka Tasaka; Azusa Akiyama; Manabu Sakurai; Sari Nakao; Hiroyuki Ochi; Mamiko Onuki; Koji Matsumoto; Hiroyuki Yoshikawa; Toyomi Satoh
Journal:  PLoS One       Date:  2018-02-21       Impact factor: 3.240

8.  The potential of RNA as a target for national screening of pre-cancer.

Authors:  Frank Karlsen; Margaret Muturi; Cosmas Muyabwa; Lars E Roseng; Serge Bigabwa; Byamungu Chihongola; Lucy Muchiri
Journal:  J Public Health Afr       Date:  2018-12-21

9.  Presence of human papilloma virus in a series of breast carcinoma from Argentina.

Authors:  Ana Laura Pereira Suarez; Mario Alejandro Lorenzetti; Rene Gonzalez Lucano; Melina Cohen; Hugo Gass; Paula Martinez Vazquez; Pedro Gonzalez; Maria V Preciado; Paola Chabay
Journal:  PLoS One       Date:  2013-04-25       Impact factor: 3.240

Review 10.  HPV E6/E7 mRNA test for the detection of high grade cervical intraepithelial neoplasia (CIN2+): a systematic review.

Authors:  Awoke Derbie; Daniel Mekonnen; Yimtubezinash Woldeamanuel; Xaveer Van Ostade; Tamrat Abebe
Journal:  Infect Agent Cancer       Date:  2020-02-07       Impact factor: 2.965

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.